Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.

Hayek SS, Landsittel DP, Wei C, Zeier M, Yu ASL, Torres VE, Roth S, Pao CS, Reiser J.

J Am Soc Nephrol. 2019 Jun 6. pii: ASN.2018121227. doi: 10.1681/ASN.2018121227. [Epub ahead of print]

PMID:
31171572
2.

Investigating the Durability of Iodine Waste Forms in Dilute Conditions.

Asmussen RM, Ryan JV, Matyas J, Crum JV, Reiser JT, Avalos N, McElroy EM, Lawter AR, Canfield NC.

Materials (Basel). 2019 Feb 26;12(5). pii: E686. doi: 10.3390/ma12050686.

3.

Nonimmune cell-derived ICOS ligand functions as a renoprotective αvβ3 integrin-selective antagonist.

Koh KH, Cao Y, Mangos S, Tardi NJ, Dande RR, Lee HW, Samelko B, Altintas MM, Schmitz VP, Lee H, Mukherjee K, Peev V, Cimbaluk DJ, Reiser J, Hahm E.

J Clin Invest. 2019 Apr 1;129(4):1713-1726. doi: 10.1172/JCI123386. Epub 2019 Mar 18.

4.

uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.

Wei C, Li J, Adair BD, Zhu K, Cai J, Merchant M, Samelko B, Liao Z, Koh KH, Tardi NJ, Dande RR, Liu S, Ma J, Dibartolo S, Hägele S, Peev V, Hayek SS, Cimbaluk DJ, Tracy M, Klein J, Sever S, Shattil SJ, Arnaout MA, Reiser J.

J Clin Invest. 2019 Apr 2;130. pii: 124793. doi: 10.1172/JCI124793. eCollection 2019 Apr 2.

5.

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.

Sommerer C, Zeier M, Morath C, Reiser J, Scharnagl H, Stojakovic T, Delgado GE, März W, Kleber ME.

Sci Rep. 2019 Jan 24;9(1):475. doi: 10.1038/s41598-018-36960-6.

6.

MeSsAGe risk score: tool for renal biopsy decision in steroid-dependent nephrotic syndrome.

Chan CY, Resontoc LP, Qader MA, Chan YH, Liu ID, Lau PY, Than M, Yeo WS, Loh AH, Tan PH, Wei C, Reiser J, Biswas SK, Ng KH, Yap HK.

Pediatr Res. 2019 Mar;85(4):477-483. doi: 10.1038/s41390-019-0277-z. Epub 2019 Jan 15.

PMID:
30659270
7.

Identification of Rabbit Oviductal Fluid Proteins Involved in Pre-Fertilization Processes by Quantitative Proteomics.

Yu H, Hackenbroch L, Meyer FRL, Reiser J, Razzazi-Fazeli E, Nöbauer K, Besenfelder U, Vogl C, Brem G, Mayrhofer C.

Proteomics. 2019 Mar;19(5):e1800319. doi: 10.1002/pmic.201800319. Epub 2019 Feb 13.

PMID:
30637940
8.

Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.

Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, Reiser J, Wei C.

BMC Nephrol. 2018 Dec 17;19(1):361. doi: 10.1186/s12882-018-1177-x.

9.

More expression, less function: cleaved dynamin in glomerular kidney disease.

Altintas MM, Reiser J.

J Pathol. 2019 Apr;247(4):413-415. doi: 10.1002/path.5217. Epub 2019 Jan 25.

PMID:
30549263
10.

Podocytes: Way to Go.

Altintas MM, Reiser J.

Am J Pathol. 2019 Feb;189(2):226-228. doi: 10.1016/j.ajpath.2018.11.003. Epub 2018 Dec 11.

PMID:
30543788
11.

Motility of human renal cells is disturbed by infection with pathogenic hantaviruses.

Hägele S, Müller A, Nusshag C, Reiser J, Zeier M, Krautkrämer E.

BMC Infect Dis. 2018 Dec 12;18(1):645. doi: 10.1186/s12879-018-3583-x.

12.

Eomesodermin driven IL-10 production in effector CD8+ T cells promotes a memory phenotype.

Reiser J, Sadashivaiah K, Furusawa A, Banerjee A, Singh N.

Cell Immunol. 2019 Jan;335:93-102. doi: 10.1016/j.cellimm.2018.11.008. Epub 2018 Dec 1.

PMID:
30528350
13.

Virus- and cell type-specific effects in orthohantavirus infection.

Hägele S, Müller A, Nusshag C, Reiser J, Zeier M, Krautkrämer E.

Virus Res. 2019 Jan 15;260:102-113. doi: 10.1016/j.virusres.2018.11.015. Epub 2018 Nov 30.

PMID:
30508604
14.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) is predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression.

Hoenigl M, Moser C, Funderburg N, Bosch R, Kantor A, Zhang Y, Eugen-Olsen J, Finkelman M, Reiser J, Landay A, Moisi D, Lederman MM, Gianella S; ACTG NWCS 411 study team.

Clin Infect Dis. 2018 Nov 12. doi: 10.1093/cid/ciy966. [Epub ahead of print]

PMID:
30418519
15.

Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR.

Shuster S, Ankawi G, Licht C, Reiser J, Wang X, Wei C, Chitayat D, Hladunewich M.

J Clin Med. 2018 Oct 4;7(10). pii: E324. doi: 10.3390/jcm7100324.

16.

Kidney-derived c-kit+ progenitor/stem cells contribute to podocyte recovery in a model of acute proteinuria.

Rangel EB, Gomes SA, Kanashiro-Takeuchi R, Saltzman RG, Wei C, Ruiz P, Reiser J, Hare JM.

Sci Rep. 2018 Oct 3;8(1):14723. doi: 10.1038/s41598-018-33082-x.

17.

Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma.

Derman BA, Reiser J, Basu S, Paner A.

Int J Nephrol. 2018 Sep 5;2018:4654717. doi: 10.1155/2018/4654717. eCollection 2018.

18.

A patient-derived orthotopic xenograft model enabling human high-grade urothelial cell carcinoma of the bladder tumor implantation, growth, angiogenesis, and metastasis.

Gills J, Moret R, Zhang X, Nelson J, Maresh G, Hellmers L, Canter D, Hudson M, Halat S, Matrana M, Marino MP, Reiser J, Shuh M, Laborde E, Latsis M, Talwar S, Bardot S, Li L.

Oncotarget. 2018 Aug 24;9(66):32718-32729. doi: 10.18632/oncotarget.26024. eCollection 2018 Aug 24.

19.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients.

Torino C, Pizzini P, Cutrupi S, Postorino M, Tripepi G, Mallamaci F, Reiser J, Zoccali C; PROGREDIRE Working Group.

Kidney Int Rep. 2018 May 22;3(5):1100-1109. doi: 10.1016/j.ekir.2018.05.004. eCollection 2018 Sep.

20.

Age-Related Differences in Pro-active Driving Behavior Revealed by EEG Measures.

Getzmann S, Arnau S, Karthaus M, Reiser JE, Wascher E.

Front Hum Neurosci. 2018 Aug 7;12:321. doi: 10.3389/fnhum.2018.00321. eCollection 2018.

21.

Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.

Lv L, Wang F, Wu L, Wang JW, Cui Z, Hayek SS, Wei C, Reiser J, He K, Zhang L, Chen M, Zhao MH.

Nephrol Dial Transplant. 2018 Aug 13. doi: 10.1093/ndt/gfy265. [Epub ahead of print]

PMID:
30124995
22.

Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in aging.

Chen D, Xie R, Shu B, Landay AL, Wei C, Reiser J, Spagnoli A, Torquati A, Forsyth CB, Keshavarzian A, Sumner DR.

Ann N Y Acad Sci. 2019 Apr;1442(1):48-60. doi: 10.1111/nyas.13945. Epub 2018 Aug 12. Review.

PMID:
30101565
23.

Stop TRPC5 in Kidney Disease: A Game Changer for Renal Allograft Protection?

Wang X, Reiser J.

Transplantation. 2018 Jul;102(7):1027-1029. doi: 10.1097/TP.0000000000002209. No abstract available.

PMID:
29952922
24.

Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.

Luo S, Coresh J, Tin A, Rebholz CM, Chen TK, Hayek SS, Tracy M, Lipkowitz MS, Appel LJ, Levey AS, Inker LA, Reiser J, Grams ME.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1013-1021. doi: 10.2215/CJN.13631217. Epub 2018 Jun 14.

PMID:
29903900
25.

ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation.

Alhamad T, Manllo Dieck J, Younus U, Matar D, Alasfar S, Vujjini V, Wall D, Kanawati B, Reiser J, Brennan DC, Alachkar N.

Transplantation. 2019 Jan;103(1):202-209. doi: 10.1097/TP.0000000000002320.

PMID:
29894413
26.

Efficiency and Specificity of Targeted Integration Mediated by the Adeno-Associated Virus Serotype 2 Rep 78 Protein.

Li P, Marino MP, Zou J, Argaw T, Morreale MT, Iaffaldano BJ, Reiser J.

Hum Gene Ther Methods. 2018 Jun;29(3):135-145. doi: 10.1089/hgtb.2018.052.

27.

Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.

Hayek SS, Divers J, Raad M, Xu J, Bowden DW, Tracy M, Reiser J, Freedman BI.

J Am Heart Assoc. 2018 May 1;7(9). pii: e008194. doi: 10.1161/JAHA.117.008194.

28.

Single-nephron proteomes connect morphology and function in proteinuric kidney disease.

Höhne M, Frese CK, Grahammer F, Dafinger C, Ciarimboli G, Butt L, Binz J, Hackl MJ, Rahmatollahi M, Kann M, Schneider S, Altintas MM, Schermer B, Reinheckel T, Göbel H, Reiser J, Huber TB, Kramann R, Seeger-Nukpezah T, Liebau MC, Beck BB, Benzing T, Beyer A, Rinschen MM.

Kidney Int. 2018 Jun;93(6):1308-1319. doi: 10.1016/j.kint.2017.12.012. Epub 2018 Mar 9.

PMID:
29530281
29.

Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.

Furusawa A, Reiser J, Sadashivaiah K, Simpson H, Banerjee A.

J Immunother. 2018 Feb/Mar;41(2):53-63. doi: 10.1097/CJI.0000000000000206.

30.

New Insights into Diabetic Kidney Disease: The Potential Pathogenesis and Therapeutic Targets.

Liu WJ, Reiser J, Park TS, Liu Z, Ishibe S.

J Diabetes Res. 2017;2017:3945469. doi: 10.1155/2017/3945469. Epub 2017 Nov 8. No abstract available.

31.

Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation.

Alasfar S, Matar D, Montgomery RA, Desai N, Lonze B, Vujjini V, Estrella MM, Manllo Dieck J, Khneizer G, Sever S, Reiser J, Alachkar N.

Transplantation. 2018 Mar;102(3):e115-e120. doi: 10.1097/TP.0000000000002008.

32.

Podocytes exhibit a specialized protein quality control employing derlin-2 in kidney disease.

Ren G, Tardi NJ, Matsuda F, Koh KH, Ruiz P, Wei C, Altintas MM, Ploegh H, Reiser J.

Am J Physiol Renal Physiol. 2018 Mar 1;314(3):F471-F482. doi: 10.1152/ajprenal.00691.2016. Epub 2017 Nov 22.

33.

Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.

Hayek SS, Ko YA, Awad M, Ahmed H, Gray B, Hosny KM, Aida H, Tracy MJ, Wei C, Sever S, Reiser J, Quyyumi AA.

Kidney Int Rep. 2017 Feb 9;2(3):425-432. doi: 10.1016/j.ekir.2017.02.001. eCollection 2017 May.

34.

TRPC5 Does Not Cause or Aggravate Glomerular Disease.

Wang X, Dande RR, Yu H, Samelko B, Miller RE, Altintas MM, Reiser J.

J Am Soc Nephrol. 2018 Feb;29(2):409-415. doi: 10.1681/ASN.2017060682. Epub 2017 Oct 23.

35.

High-content screening assay-based discovery of paullones as novel podocyte-protective agents.

Lee HW, Arif E, Altintas MM, Quick K, Maheshwari S, Plezia A, Mahmood A, Reiser J, Nihalani D, Gupta V.

Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F280-F292. doi: 10.1152/ajprenal.00338.2017. Epub 2017 Oct 18.

36.

Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.

Schaefer F, Trachtman H, Wühl E, Kirchner M, Hayek SS, Anarat A, Duzova A, Mir S, Paripovic D, Yilmaz A, Lugani F, Arbeiter K, Litwin M, Oh J, Matteucci MC, Gellermann J, Wygoda S, Jankauskiene A, Klaus G, Dusek J, Testa S, Zurowska A, Caldas Afonso A, Tracy M, Wei C, Sever S, Smoyer W, Reiser J; ESCAPE Trial Consortium and the 4C Study Group.

JAMA Pediatr. 2017 Nov 6;171(11):e172914. doi: 10.1001/jamapediatrics.2017.2914. Epub 2017 Nov 6. Erratum in: JAMA Pediatr. 2017 Nov 1;171(11):1127.

37.

Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Samman Tahhan A, Hayek SS, Sandesara P, Hajjari J, Hammadah M, O'Neal WT, Kelli HM, Alkhoder A, Ghasemzadeh N, Ko YA, Aida H, Gafeer MM, Abdelhadi N, Mohammed KH, Patel K, Arya S, Reiser J, Vaccarino V, Sperling L, Quyyumi A.

Atherosclerosis. 2017 Sep;264:108-114. doi: 10.1016/j.atherosclerosis.2017.06.019. Epub 2017 Jun 8.

38.

suPAR and chronic kidney disease-a podocyte story.

Zeier M, Reiser J.

Pflugers Arch. 2017 Aug;469(7-8):1017-1020. doi: 10.1007/s00424-017-2026-7. Epub 2017 Jul 8. Review.

PMID:
28689240
39.

Signal integration at the PI3K-p85-XBP1 hub endows coagulation protease activated protein C with insulin-like function.

Madhusudhan T, Wang H, Ghosh S, Dong W, Kumar V, Al-Dabet MM, Manoharan J, Nazir S, Elwakiel A, Bock F, Kohli S, Marquardt A, Sögüt I, Shahzad K, Müller AJ, Esmon CT, Nawroth PP, Reiser J, Chavakis T, Ruf W, Isermann B.

Blood. 2017 Sep 21;130(12):1445-1455. doi: 10.1182/blood-2017-02-767921. Epub 2017 Jul 7.

40.

A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease.

Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J.

Nat Med. 2017 Aug;23(8):945-953. doi: 10.1038/nm.4362. Epub 2017 Jun 26.

41.

Apoptosis and Compensatory Proliferation Signaling Are Coupled by CrkI-Containing Microvesicles.

Gupta KH, Goldufsky JW, Wood SJ, Tardi NJ, Moorthy GS, Gilbert DZ, Zayas JP, Hahm E, Altintas MM, Reiser J, Shafikhani SH.

Dev Cell. 2017 Jun 19;41(6):674-684.e5. doi: 10.1016/j.devcel.2017.05.014.

42.

Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.

Dande RR, Peev V, Altintas MM, Reiser J.

J Diabetes Res. 2017;2017:3232848. doi: 10.1155/2017/3232848. Epub 2017 May 17. Review.

43.

Extrarenal determinants of kidney filter function.

Hahm E, Peev V, Reiser J.

Cell Tissue Res. 2017 Jul;369(1):211-216. doi: 10.1007/s00441-017-2635-7. Epub 2017 May 30. Review.

44.

A High-Content Screening Technology for Quantitatively Studying Podocyte Dynamics.

Reiser J, Lee HW, Gupta V, Altintas MM.

Adv Chronic Kidney Dis. 2017 May;24(3):183-188. doi: 10.1053/j.ackd.2017.04.001. Review.

45.

Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.

Drechsler C, Hayek SS, Wei C, Sever S, Genser B, Krane V, Meinitzer A, März W, Wanner C, Reiser J.

Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1265-1273. doi: 10.2215/CJN.10881016. Epub 2017 May 11.

46.

Unwinding focal segmental glomerulosclerosis.

Peev V, Hahm E, Reiser J.

F1000Res. 2017 Apr 12;6:466. doi: 10.12688/f1000research.10510.1. eCollection 2017. Review.

47.

The Use of Sildenafil for Glomerular Disease.

Tardi NJ, Reiser J.

J Am Soc Nephrol. 2017 May;28(5):1329-1331. doi: 10.1681/ASN.2017020171. Epub 2017 Mar 30. No abstract available.

48.

Structural insights into the substrate recognition and reaction specificity of the PLP-dependent fold-type I isoleucine 2-epimerase from Lactobacillus buchneri.

Awad R, Gans P, Reiser JB.

Biochimie. 2017 Jun;137:165-173. doi: 10.1016/j.biochi.2017.03.015. Epub 2017 Mar 23.

PMID:
28344038
49.

Targeting mTOR Signaling Can Prevent the Progression of FSGS.

Zschiedrich S, Bork T, Liang W, Wanner N, Eulenbruch K, Munder S, Hartleben B, Kretz O, Gerber S, Simons M, Viau A, Burtin M, Wei C, Reiser J, Herbach N, Rastaldi MP, Cohen CD, Tharaux PL, Terzi F, Walz G, Gödel M, Huber TB.

J Am Soc Nephrol. 2017 Jul;28(7):2144-2157. doi: 10.1681/ASN.2016050519. Epub 2017 Mar 7.

50.

CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus.

Faridi MH, Khan SQ, Zhao W, Lee HW, Altintas MM, Zhang K, Kumar V, Armstrong AR, Carmona-Rivera C, Dorschner JM, Schnaith AM, Li X, Ghodke-Puranik Y, Moore E, Purmalek M, Irizarry-Caro J, Zhang T, Day R, Stoub D, Hoffmann V, Khaliqdina SJ, Bhargava P, Santander AM, Torroella-Kouri M, Issac B, Cimbaluk DJ, Zloza A, Prabhakar R, Deep S, Jolly M, Koh KH, Reichner JS, Bradshaw EM, Chen J, Moita LF, Yuen PS, Li Tsai W, Singh B, Reiser J, Nath SK, Niewold TB, Vazquez-Padron RI, Kaplan MJ, Gupta V.

J Clin Invest. 2017 Apr 3;127(4):1271-1283. doi: 10.1172/JCI88442. Epub 2017 Mar 6.

Supplemental Content

Loading ...
Support Center